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INTRODUCTION
Cleft lip palate (CLP) belongs to serious facial deformations
and occurs during embryogenesis, when the mesenchyme in
the lateral palatine process fails to fuse with the intermaxil-
lary segment (Norton, 2016, pp. 1–24). CLP incidence in
the world is approximately one in 1000 newborns (Murray,
2002), in comparison to data from Latvia where incidence is
one in 700 newborns (Akota et al., 2001). The facial skele-
ton is composed of two types of tissue: cartilage and bone
that are formed by chondrocytes and osteoblasts. Given that
they share a common progenitor, it is important to under-
stand which signalling pathways control the differentiation
into bone and cartilage (Hartmann, 2006). Overall, CLP af-
fects development of speech and hearing, breathing through
the nose, olfactory function, eating, and is an aesthetic de-
fect. Until this moment, surgical therapy is the method of
choice for cleft palate correction, and the need for multiple
surgeries is common (Tiwana et al., 2018). There are many
signal molecules, growth and remodellation factors, and
genes involved in the development of facial clefts and the
process of tissue healing after surgery. While studies about
signal molecules and tissue factors are found in the litera-
ture, most have investigated animal tissue, and significantly
less studies can be found about human tissue.
Matrix metalloproteinases (MMPs) and tissue inhibitors of
matrix metalloproteinases (TIMPs) are responsible for tis-
sue remodellation in the process of craniofacial develop-
ment. Additionally, degradation of extracellular matrix
(ECM) by the MMPs stimulate cell proliferation and migra-
tion (Letra et al., 2012). MMP-2 and MMP-9 are two prote-
ases that have major activity in ECM degradation and are
involved in degradation of type IV collagen as well as
laminin — major components of basal membranes. In addi-
tion, they are also associated in a variety of processes like
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Bone repair after surgical intervention on cleft lip palate (CLP) depends on the coordinated action
of multiple tissue regeneration factors. We determined the relative number and appearance of tis-
sue factors: matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase-2 (TIMP-2),
bone morphogenetic protein 2/4 (BMP 2/4), transforming growth factor beta (TGF-ß), Wnt3a pro-
tein (Wnt3a), Runt-related transcription factor 2 (Runx2), basic fibroblast growth factor (bFGF)
and osteoprotegerin in hard tissue of CLP patients during first time surgical intervention. Fourty-
three CLP patients with 24 bone and 36 cartilage samples were involved. Immunohistochemistry
was used to assess the levels of tissue factors and the semi-quantitative census method was
used for quantification of immunological structures. The increased amount of MMP-2 and bFGF
positive cells was detected in the CLP group in cartilage and bone (p < 0.05), compared to the
controls. A statistically significant (p = 0.012) increased amount of BMP 2/4 positive cells was
found in cartilage of CLP patients, in comparison to the control group. Increased appearance of
MMP-2, bFGF in hard tissue of the CLP patients indicates the predominance of tissue degrada-
tion. Increased number of BMP2/4 positive chondrocytes suggests improved cartilage growth and
better regeneration in CLP patients.
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bone remodelling, angiogenesis, immune response and tis-
sue repair. Since these MMPs are secreted as proenzymes
that require activation, their tissue distribution may not nec-
essarily reflect the sites of enzymatic activity (Gkantidis et
al., 2012). Loss of MMP in mice impairs tooth root forma-
tion, alveolar bone remodelling, and periodontal ligament
formation and integration into alveolar bone (Xu et al.,
2016).
TIMPs are also secreted into the ECM and have the ability
to inhibit the activity of MMPs. In addition, TIMPs are con-
sidered to exert pluripotential effects on cellular behaviour
such as cell growth, survival, migration, and differentiation,
independently of their MMP neutralising functions. From
the early stages of molar tooth development, location of
TIMP-2 has been shown to be associated with the ECM pre-
sented in the jaw mesenchyme on the lingual side of the
molar germ and along the lingual side of the dental base-
ment membrane (Yoshiba et al., 2007). Changed relations
in the amount in favour of the TIMPs level can also be
found in the tissue of the CLP (Verstappen et al., 2006).
Bone morphogenetic proteins (BMPs) are multifunctional
growth factors that mediate a variety of biological functions
essential for gastrulation, organogenesis and embryonic and
postnatal growth. BMPs also have an important role in the
development of cranial neural crest, facial primordia, teeth,
lips and palate. It is responsible for the migration of cells in
the neural crest, which give rise to most of the craniofacial
structures (Xuguang et al., 2006). The BMPs signal controls
cell division in the anterior palatal mesenchyme. Experi-
ments on mice showed that BMP receptor inactivation in
mesenchyme of maxillary bone could result in cleft lip and
palate (Li et al., 2013). Release of BMP-2 incorporated in
an implant increased callus mineralisation and bone healing
in the tibial bone (Faßbender et al., 2014).
Transforming growth factor ß (TGF-ß) stimulates the pro-
duction of collagen, fibronectin, proteoglycans and inhibits
collagen degradation by both decreasing MMP activity and
increasing the activity of TIMPs (Kumar et al, 2014, Chapt.
1, pp. 1–29). TGF-ß activates MMPs that are located in the
midline epithelium of palatal bones and participates in the
fusing of palatal bones (Li et al., 2017). Bone ECM is the
major storage site in the body for TGF-ß and it can be re-
leased and activated by resorbing osteoclasts, resulting in
the inhibition of osteoclast formation, activity and stimula-
tion of mature osteoblasts to produce bone matrix proteins,
although the molecular mechanism by which the TGF-ß is
released from ECM-bound stores remain unclear (Dallas et
al., 2002).
Fibroblast growth factors (FGFs) are members of a large
family of signalling proteins. FGF signalling participates in
all stages of development of palate, especially in the cell
proliferation of the palate shelves. Sonic hedgehog (Shh)
signalling is believed to be responsible for cell proliferation
in the palate mesenchyme, and Shh signalling works to-
gether with the FGF signalling via coordinated epithelial-
mesenchymal interactions (Weng et al., 2018). FGFs also
have proved to be important in the regulation of chondro-
cyte proliferation and initiation of chondrocyte hypertrophy
(Logan et al., 2004). Basic fibroblast growth factor (bFGF)
is a member of the FGF family and bFGF signalling does
not directly induce osteoblast differentiation, but is known
to modulate osteoblast differentiation. However, the exact
mechanism of the bFGF signalling in bone healing or re-
generation has not been explained (Charoenlarp et al.,
2017).
Wnt3a is a signalling molecule that belongs to the Wnt pro-
tein family and is included in various skeletogenous pro-
cesses, including cellular differentiation of the chondro-os-
seous progenitor cells, regulation of proper chondrocyte
columns in growth plate and migration processes (Logan et
al., 2004). Signalling of the Wnt results with Runx2 pro-
moter activation and induces endogenous Runx2 gene ex-
pression in pluripotent mesenchymal cells that later take a
part into bone formation (Gaur et al., 2005).
Runt-related transcription factor 2 (Runx2) belongs to the
Runx family and is a transcription factor needed for the cor-
rect structure of osteoblast cells. The BMPs and the FGFs
regulate transcription of Runx2. Runx2 also induces mesen-
chymal cell differentiation into immature osteoblasts until
the final stage of the process during which maturity of the
osteoblasts are inhibited (Komori, 2010; Dos Santos Pereira
et al., 2017). A study on Chinese patients showed that nor-
mal distribution of the Runx2 also might be a reason for
cranial dysplasia due to the mutation in the Runt domain,
which leads the impaired transaction activities of Runx2
(Zhang et al., 2017).
Osteoprotegerin (OPG) is a protein of the Tumour Necrosis
Factor (TNF) cell signalling protein family. It is the main
osteoclastogenesis modulator, also known as inhibitor of
terminal differentiation and activation of osteoclasts (Hsu et
al., 2005). OPG interacts with receptor activator of nuclear
factor B ligand (RANKL) by inhibiting binding of the
RANKL to the RANK, and therefore resulting in osteo-
clastogenesis and inhibited bone resorption (Kwan et al.,
2008). Another study confirmed that the OPG during the
osteoclastogenesis enhanced the size of osteoclasts, but at-
tenuated their bone resorbing activity, suggesting that the
OPG may play an auto regulatory role in a late phase of the
osteoclastogenesis through the induction of apoptosis (Kang
et al., 2014). Promising results exist in the therapy for
periodontitis affected tissue in rabbits. The study demon-
strated that the periodontal ligament stem cells (PDLSCs) of
gene-modified rabbits expressing human OPG achieved an
earlier mineralisation and more bone formation, which
might help to ensure the reconstruction of alveolar bone de-
fect (Su et al., 2015).
Based on all the information mentioned above, it is thought
that remodellation factors have importance in morphopatho-
genesis of CLP. Also, based on the absence of these tissue
factor’s correlative research in hard tissue of CLP patients,
the aim of our present study is to determine a relative num-
ber and appearance of the tissue factors (MMP-2, TIMP-2,
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BMP 2/4, TGF-ß, bFGF, Wnt3a, Runx2, and OPG) in hard
tissue (bone and cartilage) of CLP patients during the first
plastic alveolar osteoplasty and rhinoplasty.
MATERIALS AND METHODS
Patients. Tissue samples were obtained during first time
CLP correction surgeries, such as alveolar osteoplasty and
rhinoplasty, in the Cleft Lip and Palate Centre of the Insti-
tute of Stomatology of the Rîga Stradiòð University (RSU).
The research involved 43 patients with CLP between the
ages of 5 years 7 months to 21 years and 1 month with 24
bone tissue and 36 cartilage tissue samples (see Table 1).
Control material of bone was obtained from seven healthy
patients from the facial cleft during unrelated surgical op-
erations, due to the ethical difficulties related to receiving
permission from parents for the usage of tissue (see Table
2). Due to the ethical considerations there was no possibility
to obtain hyaline cartilage from children with facial cleft
unrelated surgeries, and therefore cartilage tissue from tra-
chea was obtained from the exposition of RSU Institute of
Anatomy and Anthropology (AAI) from subjects between
the ages of 20 to 40 years. The study was approved by the
local Ethical Committee of the Rîga Stradiòð University.
Methods. The material from patients obtained during the
first CLP correction surgery was fixated in transport test
tubes with Stefanini (Zamboni) solution and delivered to the
RSU AAI Laboratory of Morphology for further processing.
After tissue fixation, the material was rinsed for 24 hours in
Tyrode solution. An alcohol solution was used for tissue de-
watering, and tissue was placed in xylene for 30 minutes for
degreasing. The tissue was placed into paraffin for one and
two hours for the hardening process. Tissue blocks were cut
in 3 µ sections with a semi-automatic rotary microtome
(Leica RM2245, Leica Biosystems Richmond Inc., United
States). The sections were fixed on slides and dried in a
thermostat, later re-dewaxed in xylene, and dehydrated in
various alcoholic solutions.
Firstly, tissue sections were dyed with haematoxylin and
eosin for a general overview. Afterwards, for the expression
of genes and proteins we used the immunohistochemistry
method. Tissue selections were stained and processed for
the following antibodies: MMP-2 (code: ORB101049, rab-
bit, 1:400, Biorbyt USA), TIMP-2 (code: SC-21735, mouse,
1:50, Santa Cruz USA), BMP 2/4 (code: AF355, goat,
1:100, R/D Germany), TGFß1 (code: ORB7087, rabbit,
1:200, Biorbyt USA), bFGF (code: AB16828, rabbit, 1:200,
Abcam GB), Wnt3a (code: AB1992, rabbit, 1:800, Abcam
Table 1. Information on CLP patients
Patient Age Surgery procedure Patient Age Surgery procedure
No. 1 5 years 7 months Rhinoplasty No. 22 13 years 9 months Rhinoplasty
No. 2 6 years 7 months Rhinoplasty No. 23 13 years 9 months Rhinoplasty
No. 3 7 years 3 months Alveolar osteoplasty No. 24 14 years 4 months Rhinoplasty
No. 4 7 years 5 months Rhinoplasty No. 25 14 years 5 months Rhinoplasty
No. 5 7 years 7 months Rhinoplasty No. 26 15 years Rhinoplasty
No. 6 8 years 3 months Rhinoplasty No. 27 15 years 10 months Rhinoplasty
No. 7 8 years 5 months Alveolar osteoplasty No. 28 16 years Rhinoplasty
No. 8 8 years 7 months Rhinoplasty No. 29 16 years 3 months Rhinoplasty
No. 9 8 years 11 months Alveolar osteoplasty No. 30 16 years 6 months Rhinoplasty
No. 10 9 years 5 months Alveolar osteoplasty No. 31 16 years 7 months Rhinoplasty
No. 11 9 years 6 months Rhinoplasty No. 32 16 years 10 months Rhinoplasty
No. 12 9 years 11 months Alveolar osteoplasty No. 33 17 years Rhinoplasty
No. 13 12 years 7 months Rhinoplasty No. 34 18 years Rhinoplasty
No. 14 12 years 8 months Rhinoplasty No. 35 18 years Rhinoplasty
No. 15 12 years 8 months Rhinoplasty No. 36 18 years 7 months Rhinoplasty
No. 16 12 years 11 months Rhinoplasty No. 37 18 years 8 months Alveolar osteoplasty
No. 17 12 years 11 months Rhinoplasty No. 38 18 years 8 months Alveolar osteoplasty
No. 18 12 years 11 months Rhinoplasty No. 39 18 years 8 months Alveolar osteoplasty
No. 19 13 years 1 month Rhinoplasty No. 40 18 years 8 months Alveolar osteoplasty
No. 20 13 years 5 months Rhinoplasty No. 41 18 years 8 months Alveolar osteoplasty
No. 21 13 years 9 months Rhinoplasty No. 42 21 years 1 month Rhinoplasty
Table 2. Information about the control group for bone
Patient Age Surgery procedure
No. 1 6 years 9 months Tooth extraction
No. 2 9 years 9 months Tooth extraction
No. 3 10 years 2 months Tooth extraction
No. 4 10 years 5months Tooth extraction
No. 5 11 years 7 months Tooth extraction
No. 6 12 years 8 months Tooth extraction
No. 7 14 years 5 months Tooth extraction
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GB), Runx2 (code: AB192256, rabbit, 1:250, Abcam GB)
and OPG (code A0611, rabbit, 1:100, The Orbit USA).
For quantification of immunological structures we used the
semi-quantitative census method (Pilmane, 1997) as fol-
lows: (0) – no positive structure was detected in the visual
field (0 / +) – occasional positive structures seen in the vis-
ual field, (+) – few positive structures seen in the visual
field, (+ / ++) – few to moderate number of positive struc-
tures seen in the visual field, (++) – moderate number of
positive structures seen in the visual field, (++ / +++) –
moderate to numerous positive structures seen in the visual
field, (+++) – numerous positive structures seen in the vis-
ual field, (+++ / ++++) – numerous to abundant positive
structures seen in the visual field, (++++) – abundance of
positive structures seen in the visual field.
Statistical analysis of the data. For the statistical analysis
the SPSS 21.0 software version (IBM Corp., Armonk, NY,
USA) was used. Spearman’s rank correlation coefficient
(rs) was calculated for determination of correlations be-
tween values. The results were interpreted: rs = 0.4–0.59 –
moderate, positive correlation, and rs = 0.6–0.79 – strong,
positive correlation. The Mann-Whitney U-test was per-
formed for the comparison of study groups; p value < 0.05
was considered to be statistically significant.
RESULTS
OPG. OPG-positive cells were detected in all bone and car-
tilage tissue samples from the CLP and the control group.
The number of the OPG-positive osteocytes in both the con-
trol group and the CLP group was very variable, from occa-
sional to numerous, but no statistically significant differ-
ence in median numbers was found between the CLP and
the control group (U = 63.0; p = 0.610). The number of the
OPG-positive chondrocytes in the control group varied from
moderate to abundance, while in the CLP group it varied
from occasional to abundance (Fig. 1a) (see Table 3). There
was no statistically significant difference in the median
numbers of the OPG positive chondrocytes between the
CLP and the control group (U = 105.0; p = 0.051).
TGF-ß. TGF-ß positive osteocytes were observed in all
bone and cartilage samples. Few to numerous TGF-ß posi-
tive osteocytes were present in the control group, while in
the CLP group the number of TGF-ß-positive cells varied
from occasional to numerous. No statistically significant
difference in median value between the CLP group and the
control group was found (U = 37.0; p = 0.061). The number
of TGF-ß-positive chondrocytes in the control group varied
from few to moderate number to abundance, while in the
CLP group it varied from occasional to abundance (Fig. 1b)
(see Table 3). However, there was no significant difference
in median numbers of TGF-ß-positive chondrocytes be-
tween the CLP and the control group (U = 166.0; p =
0.480).
Runx2. Mainly there was an absence of Runx2-positive os-
teocytes in the control group in comparison to the CLP
group, in which the absence of the Runx2 expression was
observed only in three bone tissue samples, but relative
number of Runx2-positive cells ranged up to few. There
was no significant difference in the median numbers of
Runx2-positive cells between the groups (U = 41.0; p =
0.073). The number of Runx2-positive chondrocytes in the
control group varied from few to numerous, while in the
CLP group it varied from occasional to abundance (Fig. 1c)
(see Table 3). No statistically significant difference in me-
dian numbers between the groups was found (U = 182.5;
p = 0.903).
Wnt3a. Wnt3a-positive cells were not detected in the speci-
mens and the appearance of Wnt3a-positive osteocytes
ranged up to moderate number in both the CLP and the con-
trol group (Fig. 1d) (see Table 3). The median number of
Wnt3a-positive osteocytes was few in the control group and
occasional to few in the CLP group, but there was no statis-
tically significant difference between the groups in general
(U = 66.5; p = 0.378). In comparison to bone specimens,
Wnt3a-positive chondrocytes were found in all cartilage tis-
sue samples. Moderate number to abundant Wnt3a-positive
chondrocytes were present in the control group, while in the
CLP group the number of Wnt3a-positive structures varied
from few to abundance, showing no statistically significant
difference in median value between the study groups (U =
154.5; p = 0.377).
TIMP-2. TIMP-2-positive cells were detected in all speci-
mens. The number of TIMP-2-positive osteocytes in the
control group varied from occasional to numerous, while in
the CLP group it varied from occasional to moderate. No
statistically significant difference in median value was
found between the groups (U = 53.0; p = 0.169). The
number of TIMP-2-positive chondrocytes in the control
group varied from few to moderate number, to numerous to
abundant number, while in the CLP group it varied from
few to moderate number, to abundant (Fig. 1e) (see Table
3). No statistically significant difference between the groups
was found (U = 160.5; p = 0.555).
bFGF. bFGF-positive cells were observed in all groups.
The number of bFGF-positive osteocytes in the control
group varied from few to numerous, while in the CLP group
it varied from occasional to moderate number. The number
of bFGF positive osteocytes was significantly higher in the
CLP group than in the control group (U = 21.5; p = 0.002).
The number of bFGF-positive chondrocytes in the control
group varied from few to moderate number to moderate
number, while in the CLP group it varied from few to abun-
dant (Fig. 1f) (see Table 3). The number of bFG-positive
chondrocytes was significantly higher in the CLP group in
comparison to the control group (U = 79.0; p = 0.005).
MMP-2. Generally, there was an absence of MMP-2-
positive osteocytes in the control group, where moderate
number of MMP-2-positive structures was observed only in
one specimen, while number of MMP-2-positive structures
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in the CLP group varied from occasional to numerous (Fig.
1g) (see Table 3). We observed a significantly higher
number of MMP-2-positive osteocytes in the CLP group in
comparison to the control group (U = 27.5; p = 0.011). The
number of MMP-2-positive chondrocytes in the control
group varied from few to moderate number to moderate
number, while in the CLP group it varied from few to abun-
dant. The number of MMP-2-positive chondrocytes was sta-
tistically higher in CLP group when compared to the control
group (U = 91.5; p = 0.013).
Fig. 1. Microphotographs of a relative number in different factors of hard tissue in cleft-affected patients. (a) Numerous OPG positive chondrocytes observed
in the cartilage of 18 years old CLP patient, IMH, ×200. (b) Moderate number of TGF-ß-positive chondrocytes observed in the cartilage of a 13 year and 1
month old CLP patient, IMH, ×200. (c) Moderate number of Runx2-positive chondrocytes observed in the cartilage of a 13 year and 9 months old CLP pa-
tient, IMH, ×200. (d) Moderate number of Wnt3a-positive osteocytes observed in the bone of a 12 year and 8 months old CLP patient, IMH, ×200. (e) Nu-
merous bFGF-positive chondrocytes observed in the cartilage of a 12 year and 7 months old CLP patient, IMH, ×250. (e1) Numerous to moderate number of
bFGF-positive chondrocytes observed in the cartilage of the control patient, IMH, ×250. (f) No MMP-2-positive osteocytes observed in the bone of a 17 year
old CLP patient, IMH, ×250. (f1) No MMP-2-positive osteocytes observed in the bone of a 10 year and 5 months old control patient, IMH, ×250. (g) Numer-
ous BMP 2/4-positive chondrocytes observed in the cartilage of a 5 year and 7 months old CLP patient, IMH, ×250. (g1) Numerous BMP 2/4-positive
chondrocytes observed in the cartilage of the control patient, IMH, ×250. (h) Numerous TIMP-2-positive chondrocytes observed in the cartilage of a 12 year
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BMP 2/4. There was an absence of BMP2/4-positive osteo-
cytes in two specimens of the control group, but the results
ranged up to moderate number of positive cells, while in the
CLP group it varied from occasional to moderate number,
showing no significant difference in median value between
the CLP and the control group (U = 60.0; p = 0.232). The
number of BMP2/4-positive chondrocytes in the control
group varied from few to moderate number to moderate
number, while in the CLP group it varied from occasional
to abundant (Fig. 1h) (see Table 3). A significantly lower
number of BMP2/4 positive structures was observed in the
control group in comparison to the CLP group (U = 91.0;
p = 0.012).
Statistical data. Statistically significant (p < 0.05) strong
(rs = 0.6–0.79) correlations were found between MMP-2
and TGF-ß (rs = 0.602; p < 0.01); Runx2 and Wnt3a (rs =
0.625; p < 0.01) in CLP group bone (see Table 4).
Statistically significant (p < 0.05) moderate (rs = 0.40.59)
correlations were found between MMP-2 and BMP 2/4 (rs =
0.513; p < 0.05); MMP-2 and bFGF (rs = 0.402; p < 0.05);
MMP-2 and Wnt3a (rs = 0.488; p 0.05); MMP-2 and OPG
(rs = 0.546; p 0.01); TIMP-2 and Wnt3a (rs = 0.588; p <
0.01); TIMP-2 and TGF-ß (rs = 0.464; p < 0.01); TIMP-2
and BMP 2/4 (rs = 0.440; p < 0.05); BMP 2/4 and Wnt3a
(rs = 0.564; p < 0.01); bFGF and TGF-ß (rs = 0.504, p <
0.05); TGF-ß and Wnt3a (rs = 0.516; p < 0.05); TGF-ß and
OPG (rs = 0.578; p < 0.05); OPG and Wnt3a (rs = 0.516; p <
0.05) in the bone of the CLP group.
Statistically significant (p < 0.05) strong (rs = 0.6–0.79) cor-
relations were found between MMP-2 and bFGF (rs = 0.612;
p < 0.01); TIMP-2 and TGF-ß (rs = 0.663; p < 0.01);
TIMP-2 and BMP 2/4 (rs = 0.631; p < 0.01); BMP 2/4 and
TGF-ß (rs = 0.632; p < 0.01); BMP 2/4 and OPG (rs =
0.683; p < 0.01) in the cartilage of the CLP group (see Ta-
ble 5).
Table 3. Relative number of factor-positive cells in cartilage and bone in the control group and in CLP patients









































































Abbreviations: OPG, osteoprotegerin; TGF-ß, transforming growth factor beta; Runx2, Runt-related transcription factor 2; Wnt3a, Wnt3a protein; TIMP-2,
tissue inhibitor of metalloproteinase-2; bFGF, basic fibroblast growth factor; MMP-2, matrix metalloproteinase-2; BMP 2/4, bone morphogenetic protein 2/4.
Median value – middle number in a sorted list of numbers. Quantification of structures: 0 – no positive structures in the visual field; 0 / + – occasional posi-
tive structures in the visual field; + – few positive structures in the visual field; + / ++ – few to moderate positive structures in the visual field; ++ – moderate
positive structures in the visual field; ++ / +++ – moderate to numerous positive structures in the visual field; +++ – numerous positive structures in the visual
field; +++ / ++++ – numerous to abundance positive structures in the visual field.
Table 4. Summary of Spearman’s rank correlation analysis. Strong and
moderate relationships between numbers of positive factors in the bone of
the CLP group are shown
Factor 1 Factor 2 rs p
MMP-2 TGF-ß 0.602 < 0.01
Runx2 Wnt3a 0.625 < 0.01
MMP-2 BMP 2/4 0.513 < 0.05
MMP-2 bFGF 0.402 < 0.05
MMP-2 Wnt3a 0.488 < 0.05
MMP-2 OPG 0.546 < 0.01
TIMP-2 Wnt3a 0.588 < 0.01
BMP 2/4 Wnt3a 0.564 < 0.01
bFGF TGF-ß 0.504 < 0.05
TGF-ß Wnt3a 0.516 < 0.05
TGF-ß OPG 0.578 < 0.05
OPG Wnt3a 0.516 < 0.05
For abbreviations see Table 3.
Table 5. Summary of Spearman’s rank correlation analysis. Strong and
moderate relationships between numbers of positive factors in the bone of
the CLP group are shown
Factor 1 Factor 2 rs p
MMP-2 bFGF 0.612 < 0.01
TIMP-2 TGF-ß 0.663 < 0.01
TIMP-2 BMP 2/4 0.631 < 0.01
BMP 2/4 TGF-ß 0.632 < 0.01
BMP 2/4 OPG 0.683 < 0.01
MMP-2 TGF-ß 0.592 < 0.01
MMP-2 Wnt3a 0.484 < 0.01
TIMP-2 bFGF 0.457 < 0.01
TIMP-2 Runx2 0.464 < 0.01
TIMP-2 OPG 0.572 < 0.01
BMP 2/4 Wnt3a 0.496 < 0.01
BMP 2/4 Runx2 0.409 < 0.01
bFGF TGF- ß 0.536 < 0.01
bFGF OPG 0.578 < 0.01
For abbreviations see Table 3.
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Statistically significant (p < 0.05) moderate (rs = 0.4–0.59)
correlations were found between MMP-2 and TGF-ß (rs =
0.592; p < 0.01); MMP-2 and Wnt3a (rs = 0.484; p < 0.01);
TIMP-2 and bFGF (rs = 0.457; p < 0.01); TIMP-2 and
Runx2 (rs = 0.464; p < 0.01); TIMP-2 and OPG (rs = 0.572;
p < 0.01); BMP 2/4 and Wnt3a (rs = 0.496; p < 0.01); BMP
2/4 and Runx2 (rs = 0.409; p < 0.01); bFGF and TGF-ß (rs =
0.536; p < 0.01); bFGF and OPG (rs = 0.578; p < 0.01) in
the cartilage of the CLP group.
DISCUSSION
In this study, we sought to understand the mechanisms that
participate in bone and cartilage remodelling in CLP pa-
tients and possible outcomes related to tissue healing after a
surgical intervention. Bone repair after surgical intervention
depends on the coordinated action of multiple tissue regen-
eration factors. The numbers and distribution of the tissue
factors that may have a role in regeneration have not been
widely investigated.
OPG is the main osteoclastogenesis modulator, also known
as inhibitor of terminal differentiation and activation of os-
teoclasts (Hsu et al., 2005). Periodontal ligament stem cells
of rabbits expressing human OPG achieved earlier minerali-
sation and gained more bone formation that could help to
reconstruct alveolar bone defect (Su et al., 2015). There is
evidence that endogenous OPG protects against cartilage
destruction in osteoarthritis (Shimizu et al., 2007). In con-
trast, Takegami et al. (2017) found that OPG may play a
part in the opposite mechanism — progression of the carti-
lage degeneration that is seen in inflamed intravertebral
discs (Takegami et al., 2017). Although our study showed
no statistically significant difference between the CLP
group and the control group, more pronounced numbers of
OPG positive cells were found in chondrocytes of CLP pa-
tient cartilage in comparison to bone. Correlations found be-
tween OPG and bFGF and BMP2/4 could indicate increased
cartilage tissue proliferation instead of mineralisation.
Runx is necessary for the correct structure of osteoblast
cells. It promotes bone mineralisation, osteoblast prolifera-
tion and induces mesenchymal cell differentiation into im-
mature osteoblasts until the final stage of the process in
which maturity of osteoblasts is inhibited (Dos Santos
Pereira et al., 2017). Our results indicated that there was no
statistically significant difference between the CLP group
and the control group, but the numbers of Runx2 positive
structures in the bone and cartilage tissue was low, indicat-
ing reduced mineralisation potential of the hard tissue.
Similar results were reported by Stricker et al. (2002) where
Runx2 negative chicken embryos showed a decrease of en-
dochondral ossiffication, which was caused by delay in
chondrocyte maturation.
Wnt3a signalling increases bone formation through the
stimulation of the development of osteoblasts, and inhibi-
tion of osteoblast and osteocyte apoptosis (Krishnan et al.,
2006). Variation in Wnt3a, which is one of factors responsi-
ble for neural crest cell development and migration, is asso-
ciated with CLP (Chiquet et al., 2008). In our study there
was no statistically significant difference in Wnt3a positive
cells between the CLP group and the control group, but we
found a difference in relative numbers between bone and
cartilage tissue. The lower number of Wnt3a-positive struc-
tures in bone could result in decreased mineralisation and
ossification ability in comparison to cartilage where a mod-
erate number of positive structures was observed. Therefore
we assume that the initial ossification process could take
place in the cartilage tissue for patients with CLP.
MMPs are responsible for tissue remodellation, degradation
of ECM, cell proliferation, and tissue repair. Absence in
MMP-2 can lead to loss of bone mineral density, cartilage
destruction, and abnormal craniofacial development with
decreases in osteoblast and osteoclast numbers in vivo, lead-
ing to impaired skeletal development (Mosig et al., 2007).
A recent study demonstrated that loss of MMP in mice con-
cludes with dentoalveolar tissue defect (Xu et al., 2016).
This concurs with another study that demonstrated in-
creased MMP-2 expression in the bone healing process by
osteoblasts and osteocytes (Itagaki et al., 2008). In our
study we observed a statistically significant (p < 0.05) in-
creased amount of MMP-2 in CLP patients, both in carti-
lage and bone, compared to the control group, which could
show that alveolar bone and nasal cartilage remodellation
and healing is more pronounced in CLP patients. That could
mean that tissue are more requisite for tissue repair and in-
creased levels of MMP-2-positive cells could indicate the
beginning of healing after surgical intervention. Strong cor-
relation between MMP-2 and TGF-ß (rs = 0.602) in bone
and MMP-2 and bFGF (rs = 0.612) in cartilage would sup-
port the process of increased tissue proliferation and
remodellation.
TIMPs have the ability to inhibit the activity of MMPs and
have effects on growth, survival, migration, and differentia-
tion, and have an essential role in formation and maturation
of the bone (Yoshiba et al., 2007). TIMP-2 inhibits bone re-
sorption and degradation of the organic matrix, which
mainly consists of collagen I, therefore, remodelling bone.
An imbalance of active MMPs over TIMPs is responsible
for increased bone loss in pathological processes (Hill et al.,
1993). It has been found that osteoblasts and osteocytes in
the incorporated bone also increasingly express TIMP2
(Hatori et al., 2004). Polymorphism in TIMP2 is associated
with the development of facial clefts (Letra et al., 2012). In
our research no statistically significant difference was found
between the CLP group and the control group, but the in-
creased levels of TIMP2 and strong correlations between
TIMP2 and BMP2/4 (rs = 0.602) and TIMP2 and TGF-ß (rs
= 0.602) in chondrocytes in comparison to osteocytes may
suggest better healing potential in the cartilage.
TGF-ß acts as inhibitor for MMP activity and increases the
activity of TIMPs, therefore it inhibits collagen degradation
and stimulates collagen production (Mitchell, 2017). TGF-ß
negatively regulates osteoclastogenesis by increasing levels
of OPG in osteoblasts. The addition of TGF-ß as exogenous
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applications in orthodontic treatment may be an approach to
prevent periodontal damage (Yang et al., 2014). In our
study, there was no statistically significant difference be-
tween the CLP group and the control group in TGF-ß-posi-
tive cells. However, larger numbers of TGF-ß were found in
cartilage, therefore indicating better tissue regeneration abil-
ity.
FGFs are potent angiogenic factors and have an important
role in embryonic development and wound healing, angio-
genesis, tissue repair and regeneration (Powers et al., 2000).
FGF signalling participates in all stages of palatogenesis,
especially in cell proliferation during palatal fusion, and dis-
turbance of this process in the central neural crest would
cause a failure of palatal shelf fusion and would result in
CLP (Weng et al., 2018). A greater amount of new cemen-
tum deposits and new bone formation was observed six
weeks after bFGF applications to bone defects created in
dogs (Murakami et al., 2003). In our study, we observed a
statistically significant (p < 0.05) increase in amount of
bFGF in the cartilage and bone of the CLP patients in com-
parison to the control group. These observations may sug-
gest that increased proliferation and hypertrophy takes place
in both chondrocytes and osteocytes in CLP patients, which
could indicate a better possibility for successful wound
healing.
BMP signal is critical for sceletogenesis due to regulation
of chondrogenesis and osteogenesis. BMP signalling is in-
volved in determination, migration, proliferation, differenti-
ation and apoptosis of skeletal cells (Nie et al., 2006). Dis-
turbance in BMP-4 signalling pathways and genetic
polymorphisms presented with diminished cell proliferation
in maxillary process mesenchyme (Liu et al., 2005) and is
clinically significant in the development and progression of
CLP (Lin et al., 2008). It is concluded that BMP applica-
tions could influence endochondral ossification, thereby ac-
celerating fracture healing (Wang et al., 2017) and also it
has properties to increase proteoglycans and collagen pro-
duction in the bone at the place of osteoplasty (Sekiya et al.,
2005). BMP-2 has the ability to induce mesenchymal cells
to differentiate into osteoblast cells. Herford et al. showed
that premaxillary osseous clefts, repaired with the material
filled with BMP-2, could result in efficacious bone repair
without autogenous bone carrier graft (Herford et al., 2007).
There was no statistically significant difference found be-
tween the CLP group and the control group for bone, but a
statistically significant (p = 0.012) increased amount of
BMP 2/4 was found in the cartilage of the CLP patients in
comparison to the controls. We obtained statistically signifi-
cant strong correlations between BMP2/4 and TIMP2 (rs =
0.631) and BMP2/4 and TGF-ß (rs = 0.632) which may sug-
gest increased tissue proliferation and healing capacities in
cartilage that exceeds bone healing.
CONCLUSIONS
Increased appearance of MMP2, bFGF positive structures in
hard tissue of the CLP patients indicates the predominance
of tissue degradation of mesodermal origin tissue.
Increased number of BMP2/4 positive chondrocytes sug-
gests the elevation of cartilage growth and thus better regen-
eration in the cleft lip palate.
Slight predominance of OPG, Wnt3a, TIMP2, TGF-ß-posi-
tive structures in cartilage (although without the statistically
significant difference) proves the tendency for higher carti-
lage plasticity, including regeneration in cleft affected tis-
sue.
The observed low number of OPG and Runx2 positive cells
in bone could indicate a reduced mineralisation potential in
bone in the case of CLP.
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AUDU REMODELÂCIJAS FAKTORU SASTOPAMÎBA UN ATRADNE LÛPU UN AUKSLÇJU ÐÍELTÒU PACIENTU
BALSTAUDOS
Kaulu dzîðana pçc lûpu un aukslçju ðíeltòu íirurìiskas korekcijas ir atkarîga no vairâku faktoru savstarpçjas mijiedarbîbas. Ðajâ pçtîjumâ
tika novçrtçts audu faktoru (MMP-2, TIMP-2, BMP 2/4, TGF-ß, Wnt3a, Runx2, bFGF un OPG) relatîvais daudzums ðíeltnes skartu
pacientu un kontroles grupas balstaudos. Pçtîjumâ tika iekïauti 43 lûpas un aukslçju ðíeltnes skarti pacienti un analizçti 24 kaulaudu paraugi
un 36 skrimðïaudu paraugi. Kontroles grupas materiâls tika iegûts ar ðíeltni nesaistîtu operâciju rezultâtâ. Imûnhistoíîmiski noteikto un
analizçto struktûru kvantifikâcijai tika izmantota puskvantitatîvâ skaitîðanas metode. Ðíeltnes pacientu kaulaudos un skrimðïaudos tika
novçrots palielinâts MMP-2 un bFGF pozitîvo ðûnu daudzums, salîdzinot ar kontroles grupu, kas norâda uz audu degradâcijas predominanci
ðíeltnes pacientu balstaudos. BMP 2/4 pozitîvo ðûnu daudzums ðíeltnes pacientu skrimðïaudos bija statistiski ticami lielâks (p = 0,012)
nekâ kontroles grupas pacientiem. Palielinâts BMP2/4 pozitîvo ðûnu daudzums ðíeltnes skartu pacientu skrimðïaudos norâda uz palielinâtu
skrimðïa augðanu un tâdçjâdi labâku skrimðïa reìenerâciju lûpas un aukslçju ðíeltnes pacientiem. Samazinâts OPG un Runx2 pozitîvo ðûnu
daudzums ðíeltnes pacientu kaulaudos varçtu norâdît uz samazinâtu kaula mineralizâcijas potenciâlu. Aukslçju ðíeltòu gadîjumâ audu
proliferâcijas un remodelçðanas procesi dominç pâr mineralizâcijas procesu.
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